Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by 
All the vital news, analysis, and commentary curated by our industry experts.
Hereditary Angioedema (HAE) Pipeline Drugs Development Market Overview
Hereditary Angioedema (HAE) is a rare inherited disease that causes considerable swelling in various body tissues, such as the abdomen or face. Symptoms include severe abdominal pain and cramping, dehydration, diarrhea and shock, hoarse voice, difficulty swallowing and difficulty breathing. Treatment includes medications, such as epinephrine, antihistamines, and corticosteroids.
The Hereditary Angioedema pipeline drugs market research report provides comprehensive information on the therapeutics under development for Hereditary Angioedema, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report offers an overview of key players involved in therapeutic development for Hereditary Angioedema and features dormant and discontinued projects.
| Key Targets | Plasma Kallikrein, Coagulation Factor XII, Complement C1s Subcomponent, Plasma Protease C1 Inhibitor, and B2 Bradykinin Receptor |
| Key Mechanisms of Action | Plasma Kallikrein Inhibitor, Coagulation Factor XII Inhibitor, Complement C1s Subcomponent Inhibitor, Plasma Protease C1 Inhibitor Activator, B2 Bradykinin Receptor Antagonist, and Plasma Protease C1 Inhibitor Replacement |
| Key Routes of Administration | Subcutaneous, Intravenous, Oral, Intradermal, and Intramuscular |
| Key Molecule Types | Small Molecule, Monoclonal Antibody, Recombinant Protein, Gene Therapy, Antisense Oligonucleotide, Oligonucleotide, Protein, and Gene-Modified Cell Therapy |
| Key Companies | CSL Ltd, Kalvista Pharmaceuticals Inc, Pharming Group NV, and Attune Pharmaceuticals among others |
| Enquire & Decide | Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
Hereditary Angioedema Pipeline Drugs Market Segmentation by Targets
Some of the targets of the Hereditary Angioedema pipeline drugs market are Plasma Kallikrein, Coagulation Factor XII, Complement C1s Subcomponent, Plasma Protease C1 Inhibitor, and B2 Bradykinin Receptor. Plasma Kallikrein led this segment of the Hereditary Angioedema pipeline drugs market in 2022.
Hereditary Angioedema Pipeline Drugs Market Analysis by Targets, 2022 (%)
For more Hereditary Angioedema pipeline drugs market target insights, download a free report sample
Hereditary Angioedema Pipeline Drugs Market Segmentation by Mechanisms of Action
Some of the key mechanisms of action of the Hereditary Angioedema pipeline drugs market are Plasma Kallikrein Inhibitor, Coagulation Factor XII Inhibitor, Complement C1s Subcomponent Inhibitor, Plasma Protease C1 Inhibitor Activator, B2 Bradykinin Receptor Antagonist, and Plasma Protease C1 Inhibitor Replacement. Plasma Kallikrein Inhibitor accounted for the largest Hereditary Angioedema pipeline drugs market share in terms of MoA in 2022.
Hereditary Angioedema Pipeline Drugs Market Analysis by Mechanisms of Action, 2022 (%)
For more mechanisms of action insights into the Hereditary Angioedema pipeline drugs market, download a free report sample
Hereditary Angioedema Pipeline Drugs Market Segmentation by Routes of Administration
The key routes of administration in the Hereditary Angioedema pipeline drugs market are subcutaneous, intravenous, oral, intradermal, and intramuscular. In 2022, the subcutaneous segment led the Hereditary Angioedema pipeline drugs market in terms of RoA.
Hereditary Angioedema Pipeline Drugs Market Analysis by Routes of Administration, 2022 (%)
For more routes of administration insights into the Hereditary Angioedema pipeline drugs market, download a free report sample
Hereditary Angioedema Pipeline Drugs Market Segmentation by Molecule Types
The molecule types in the Hereditary Angioedema pipeline drugs market are small molecule, monoclonal antibody, recombinant protein, gene therapy, antisense oligonucleotide, oligonucleotide, protein, and gene-modified cell therapy. Small molecule held the largest Hereditary Angioedema pipeline drugs market share in terms of molecule types.
Hereditary Angioedema Pipeline Drugs Market Analysis by Molecule Types, 2022 (%)
For more molecule-type insights into the Hereditary Angioedema pipeline drugs market, download a free report sample
Hereditary Angioedema Pipeline Drugs Market - Competitive Landscape
Some of the key companies in the Hereditary Angioedema pipeline drugs market are CSL Ltd, Kalvista Pharmaceuticals Inc, Pharming Group NV, and Attune Pharmaceuticals among others. CSL Ltd Inc had the highest number of products under development in 2022.
CSL Ltd: CSL Ltd (CSL) discovers, develops, manufactures, commercializes, and distributes biopharmaceuticals and related products. Its portfolio encompasses plasma-derived products for the treatment of hemophilia, hereditary angioedema, von Willebrand disease, inherited primary and secondary immune deficiencies, respiratory disease, neurological disorders, and protein-based medicines for treating serious human illnesses. The company also provides products for the prevention of hemolytic disease in newborns, infection in solid organ transplant recipients and to treat specific infections for victims of trauma and burns. CSL markets an array of vaccines, anti-venom, and pharmaceutical products for various other manufacturers. The company sells its products in Australia, Germany, Switzerland, the UK, the US and other countries. CSL is headquartered in Parkville, Victoria, Australia.
Hereditary Angioedema Pipeline Drugs Market Analysis by Companies, 2022 (%)
To know more about the Hereditary Angioedema pipeline drugs market companies, download a free report sample
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Hereditary Angioedema.
- The pipeline guide reviews pipeline therapeutics for Hereditary Angioedema by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hereditary Angioedema therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hereditary Angioedema therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews the latest news related to pipeline therapeutics for Hereditary Angioedema
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with a potentially strong product portfolio and create effective counterstrategies to gain a competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hereditary Angioedema.
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding the Hereditary Angioedema pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understanding from the know-how what drove them from the pipeline.
Astria Therapeutics Inc
Attune Pharmaceuticals
BioMarin Pharmaceutical Inc
Bioviz Technologies Pvt Ltd
Bridge Medicines LLC
CAMP4 Therapeutics Corp
CSL Ltd
Intellia Therapeutics Inc
Ionis Pharmaceuticals Inc
Kalvista Pharmaceuticals Inc
Octapharma AG
Pharming Group NV
Pharvaris NV
Ractigen Therapeutics Inc
Spark Therapeutics Inc
Takeda Pharmaceutical Co Ltd
Verseon Corp
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets of the Hereditary Angioedema pipeline drugs market?
Some of the targets of the Hereditary Angioedema pipeline drugs market are Plasma Kallikrein, Coagulation Factor XII, Complement C1s Subcomponent, Plasma Protease C1 Inhibitor, and B2 Bradykinin Receptor.
-
What are the key mechanisms of action in the Hereditary Angioedema pipeline drugs market?
Some of the mechanisms of action of the Hereditary Angioedema pipeline drugs market are Plasma Kallikrein Inhibitor, Coagulation Factor XII Inhibitor, Complement C1s Subcomponent Inhibitor, Plasma Protease C1 Inhibitor Activator, B2 Bradykinin Receptor Antagonist, and Plasma Protease C1 Inhibitor Replacement.
-
What are the key routes of administration in the Hereditary Angioedema pipeline drugs market?
The key routes of administration in the Hereditary Angioedema pipeline drugs market are subcutaneous, intravenous, oral, intradermal, and intramuscular.
-
What are the key molecule types in the Hereditary Angioedema pipeline drugs market?
The molecule types in the Hereditary Angioedema pipeline drugs market are small molecule, monoclonal antibody, recombinant protein, gene therapy, antisense oligonucleotide, oligonucleotide, protein, and gene-modified cell therapy.
-
Which are the leading companies in the Hereditary Angioedema pipeline drugs market?
Some of the leading companies in the Hereditary Angioedema pipeline drugs market are CSL Ltd, Kalvista Pharmaceuticals Inc, Pharming Group NV, and Attune Pharmaceuticals among others.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Sample Report
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:
- Assess the relevance of the report
- Evaluate the quality of the report
- Justify the cost
Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.
Related reports
View more Immunology reports